The predictive value of early molecular response by relative risk in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from the phase 3 DASISION trial

被引：0
|
作者：
Stegelmann, F. [1 ]
Shah, N. P. [2 ]
Saglio, G. [3 ]
Hochhaus, A. [4 ]
Bilmes, R. [5 ]
Li, L. [5 ]
Cortes, J. E. [6 ]
机构：
[1] Univ Klinikum Ulm, Ulm, Germany
[2] UCSF, Sch Med, San Francisco, CA USA
[3] Univ Turin, Turin, Italy
[4] Univ Klinikum Jena, Jena, Germany
[5] Bristol Myers Squibb, Princeton, NJ USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V158
引用
收藏
页码：40 / 40
页数：1
相关论文
共 50 条
  • [41] Watching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial
    Cortes, Jorge E.
    De Souza, Carmino Antonio
    Lopez, Jose Luis
    Ayala, Manuel
    Bullorsky, Eduardo
    Huang, Xiaojun
    Shah, Sandip
    Babu, K. Govind
    Sacha, Tomasz
    Bendit, Israel
    Liang, Zhizhou
    Owugah, Tina
    Nidamarthy, Prasanna Kumar
    Szczudlo, Tomasz
    Piccolo, Carmen
    le Coutre, Philipp D.
    BLOOD, 2013, 122 (21)
  • [42] Dasatinib lack of cross intolerance to imatinib in patients (pts) with chronic myelogenous leukemia chronic phase (CML-CP) intolerant to imatinib: a retrospective analysis of safety
    Khoury, H. J.
    Goldberg, S. L.
    Mauro, M. J.
    Stone, R. M.
    Matloub, Y.
    Chen, T.
    Guilhot, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] EFFICACY AND SAFETY OF DASATINIB VS. IMATINIB IN LATIN AMERICAN SUBPOPULATION FROM THE DASISION TRIAL IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE (CP)
    Enrico, A.
    Milone, J.
    Moiraghi, B.
    Casanova, L.
    Undurraga, M. S.
    Olivera, L. Enciso
    Bullorsky, E.
    Navarro Cabrera, J.
    Pagnano, K.
    De Riz, M.
    Pavlovsky, C.
    HAEMATOLOGICA, 2015, 100 : 446 - 447
  • [44] MOLECULAR RESPONSE KINETICS AND BCR-ABL REDUCTIONS IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) RECEIVING DASATINIB VS IMATINIB: DASISION 3-YEAR FOLLOW-UP
    Hochhaus, A.
    Boque, C.
    Bradley Garelik, M.
    Manos, G.
    Steegmann, J. L.
    HAEMATOLOGICA, 2012, 97 : 76 - 76
  • [45] Nilotinib-Associated Molecular Responses Achieved in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients with a Suboptimal Molecular Response to Imatinib
    Yang, Allen S.
    Jillella, Anand
    Miller, Carole B.
    Akard, Luke P.
    DeAngelo, Daniel J.
    Goldberg, Stuart L.
    Williams, Denise
    Radich, Jerald P.
    BLOOD, 2009, 114 (22) : 868 - 869
  • [46] ANALYSIS OF DASATINIB AND IMATINIB 5-YEAR EFFICACY AND SAFETY BASED ON BASELINE COMORBIDITY AND AGE IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) IN DASISION
    Saglio, G.
    Cortes, J. E.
    Hochhaus, A.
    Shah, N. P.
    Atallah, E. L.
    Abaskharoun, M.
    Li, L.
    Mauro, M. J.
    HAEMATOLOGICA, 2017, 102 : 436 - 437
  • [47] Dasatinib as initial therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop
    O'Brien, Susan
    Luthra, Raja
    Jabbour, Elias
    Quintas-Cardama, Aflonso
    Borthakur, Gautam
    Ravandi, Farhad
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge
    CANCER RESEARCH, 2011, 71
  • [48] Resistance, Outcome and the Development of Mutations with Dasatinib in Patients with Chronic-Phase Chronic Myeloid Leukemia (CML-CP).
    Shah, Neil
    Bahceci, Erkut
    Lambert, Alexandre
    Ploughman, Lynn
    Radich, Jerald
    BLOOD, 2009, 114 (22) : 460 - 460
  • [49] Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Hochhaus, Andreas
    Saglio, Giuseppe
    Hughes, Timothy P.
    Larson, Richard A.
    Taningco, Lilia
    Deng, Weiping
    Menssen, Hans D.
    Kantarjian, Hagop M.
    BLOOD, 2015, 126 (23)
  • [50] FINAL LASOR RESULTS: SWITCH TO NILOTINIB (NIL) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP) AND SUBOPTIMAL CYTOGENETIC RESPONSE (CYR) TO FRONTLINE IMATINIB (IM)
    le Coutre, P. D.
    Shah, S.
    De Souza, C. A.
    Ayala, M.
    Lopez, J. L.
    Bullorsky, E.
    Shen, Z. X.
    de Oliveira, J. S. R.
    Sacha, T.
    Bendit, I.
    Liang, Z.
    Owugah, T.
    Khanna, S.
    Fellague-Chebra, R.
    Babu, K. G.
    Cortes, J. E.
    HAEMATOLOGICA, 2015, 100 : 63 - 63
12345